Samsung Bioepis Co., Ltd.

Reacting to a recently-filed lawsuit from Johnson & Johnson that is seeking to stop partners Samsung Bioepis and Sandoz from introducing a private-label ustekinumab biosimilar rival to Stelara in

Amgen has launched its Bkemv (eculizumab-aeeb) biosimilar to Alexion’s Soliris in the US, entering the market as the first interchangeable biosimilar to the brand under the terms of a settlement agree

Stelara (ustekinumab) biosimilars are now available from multiple suppliers in the US, after Teva, Sandoz and Biocon Biologics confirmed launches under settlements with originator J&J, while sever

Within 24 hours of Samsung Bioepis and Sandoz launching their partnered Pyzchiva (ustekinumab-ttwe) biosimilar to Stelara in the US, the Korean developer has been hit by a lawsuit from originator J&am